Targeting leukemia inhibitory factor in pancreatic adenocarcinoma

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. Ca A Cancer J Clinicians. 2022;72(1):7–33. DOI:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913–2921.
   PubMed Web of Science ®Google Scholar
• Long J, Zhang Y, Yu X, et al. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 2011;15(7):817–828. DOI:10.1517/14728222.2011.566216
   PubMed Web of Science ®Google Scholar
• Kommalapati A, Tella SH, Goyal G, et al. Contemporary management of localized resectable pancreatic cancer. Cancers (Basel). 2018;10(1):24. DOI:10.3390/cancers10010024
   PubMed Web of Science ®Google Scholar
• Wood LD, Canto MI, Jaffee EM, et al. Pancreatic Cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022 Aug;163(2):386–402.e1.
   PubMed Web of Science ®Google Scholar
• Robatel S, Schenk M. Current limitations and novel perspectives in Pancreatic cancer treatment. Cancers (Basel). 2022;14(4):985.
   PubMed Web of Science ®Google Scholar
• Zeng S, Pöttler M, Lan B, et al. Chemoresistance in Pancreatic cancer. Int J Mol Sci. 2019;20(18):4504. DOI:10.3390/ijms20184504
   PubMed Web of Science ®Google Scholar
• Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. Ca A Cancer J Clinicians. 2000;50(1):7–33. DOI:10.3322/canjclin.50.1.7
   PubMed Web of Science ®Google Scholar
• McCarroll JA, Naim S, Sharbeen G, et al. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol. 2014;5:141.
   PubMed Web of Science ®Google Scholar
• Wang M-T, Fer N, Galeas J, et al. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun. 2019;10(1):1–10. DOI:10.1038/s41467-019-11044-9
   PubMed Web of Science ®Google Scholar
• Shi Y, Gao W, Lytle NK, et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019 May;569(7754):131–135. DOI:10.1038/s41586-019-1130-6
   PubMed Web of Science ®Google Scholar
• Schwertman P, Bekker-Jensen S, Mailand N. Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers. Nat Rev Mol Cell Biol. 2016;17(6):379–394.
   PubMed Web of Science ®Google Scholar
• Li X, Yang Q, Yu H, et al. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-Mtor pathway. Oncotarget. 2014;5(3):788. DOI:10.18632/oncotarget.1772
   PubMedGoogle Scholar
• Liu S-C, Tsang N-M, Chiang W-C, et al. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J Clin Investig. 2013;123(12):5269–5283. DOI:10.1172/JCI63428
   PubMed Web of Science ®Google Scholar
• Yu H, Yue X, Zhao Y, et al. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun. 2014;5(1):1–12. DOI:10.1038/ncomms6218
   Google Scholar
• Kuphal S, Wallner S, Bosserhoff AK. Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma. Exp Mol Pathol. 2013;95(2):156–165.
   PubMed Web of Science ®Google Scholar
• Jiang W, Bai W, Li J, et al. Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer. Int J Cancer. 2021 Feb 15;148(4):1006–1013. DOI:10.1002/ijc.33291
   PubMed Web of Science ®Google Scholar
• Gearing D, Gough N, King J, et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). Embo J. 1987;6(13):3995–4002. DOI:10.1002/j.1460-2075.1987.tb02742.x
   PubMed Web of Science ®Google Scholar
• Nicola NA, Babon JJ. Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 2015 Oct;26(5):533–544.
   PubMed Web of Science ®Google Scholar
• Charnock-Jones D, Sharkey A, Fenwick P, et al. Leukaemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRNA for the receptor at this time. Reproduction. 1994;101(2):421–426. DOI:10.1530/jrf.0.1010421
   Web of Science ®Google Scholar
• Walker EC, McGregor NE, Poulton IJ, et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Investig. 2010;120(2):582–592. DOI:10.1172/JCI40568
   PubMed Web of Science ®Google Scholar
• Sims NA, Johnson RW. Leukemia inhibitory factor: a paracrine mediator of bone metabolism. Growth Factors. 2012;30(2):76–87.
   PubMed Web of Science ®Google Scholar
• Yano H, Readhead C, Nakashima M, et al. Pituitary-directed leukemia inhibitory factor transgene causes Cushing’s syndrome: neuro-immune-endocrine modulation of pituitary development. Mol Endocrinol. 1998;12(11):1708–1720. DOI:10.1210/mend.12.11.0200
   PubMed Web of Science ®Google Scholar
• Yoshida T, Satoh M, Nakagaito Y, et al. Cytokines affecting survival and differentiation of an astrocyte progenitor cell line. Dev Brain Res. 1993;76(1):147–150. DOI:10.1016/0165-3806(93)90132-T
   PubMedGoogle Scholar
• Patterson PH, Chun LL. The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons: iI. Developmental aspects. Dev Biology. 1977;60(2):473–481.
   PubMed Web of Science ®Google Scholar
• Austin L, Burgess A. Stimulation of myoblast proliferation in culture by leukaemia inhibitory factor and other cytokines. J Neurolog Sci. 1991;101(2):193–197.
   PubMed Web of Science ®Google Scholar
• Sheng Z, Pennica D, Wood WI, et al. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development. 1996;122(2):419–428. DOI:10.1242/dev.122.2.419
   PubMed Web of Science ®Google Scholar
• Metcalfe S. LIF in the regulation of T-cell fate and as a potential therapeutic. Genes & Immunity. 2011;12(3):157–168.
   PubMed Web of Science ®Google Scholar
• Stahl N, Boulton TG, Farruggella T, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science. 1994 Jan 7;263(5143):92–95.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998 May 1;93(3):373–383.
   PubMed Web of Science ®Google Scholar
• Boulanger MJ, Bankovich AJ, Kortemme T, et al. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell. 2003 Sep;12(3):577–589.
   PubMed Web of Science ®Google Scholar
• Gulluoglu S, Sahin M, Tuysuz EC, et al. Leukemia inhibitory factor promotes aggressiveness of chordoma. Oncol Res. 2017;25(7):1177–1188. DOI:10.3727/096504017X14874349473815
   PubMed Web of Science ®Google Scholar
• Hirai H, Karian P, Kikyo N. Regulation of embryonic stem cell self-renewal and pluripotency by leukaemia inhibitory factor. Biochem J. 2011 Aug 15;438(1):11–23.
   PubMedGoogle Scholar
• Cartwright P, McLean C, Sheppard A, et al. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development. 2005 Mar;132(5):885–896.
   PubMed Web of Science ®Google Scholar
• Forrai A, Boyle K, Hart AH, et al. Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cells. Stem Cells. 2006 Mar;24(3):604–614.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Carpino N, Cross JC, et al. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. Embo J. 2003;22(3):372–384. DOI:10.1093/emboj/cdg057
   PubMed Web of Science ®Google Scholar
• Niwa H, Burdon T, Chambers I, et al. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998;12(13):2048–2060. DOI:10.1101/gad.12.13.2048
   PubMed Web of Science ®Google Scholar
• Graf U, Casanova EA, Cinelli P. The role of the Leukemia Inhibitory Factor (LIF) - pathway in derivation and maintenance of murine pluripotent stem cells. Genes (Basel). 2011 Mar 9;2(1):280–297.
   PubMed Web of Science ®Google Scholar
• Schere-Levy C, Buggiano V, Quaglino A, et al. Leukemia inhibitory factor induces apoptosis of the mammary epithelial cells and participates in mouse mammary gland involution. Exp Cell Res. 2003 Jan 1;282(1):35–47.
   PubMed Web of Science ®Google Scholar
• Chapman RS, Lourenco P, Tonner E, et al. The role of Stat3 in apoptosis and mammary gland involution. Conditional deletion of stat3. Adv Exp Med Biol. 2000;480:129–138.
   PubMed Web of Science ®Google Scholar
• Hughes K, Watson CJ. The spectrum of STAT functions in mammary gland development. JAKSTAT. 2012 Jul 1;1(3):151–158.
   PubMedGoogle Scholar
• Calses PC, Crawford JJ, Lill JR, et al. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer. 2019 May;5(5):297–307.
   PubMed Web of Science ®Google Scholar
• Chen D, Sun Y, Wei Y, et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012 Oct;18(10):1511–1517.
   PubMed Web of Science ®Google Scholar
• Vlug EJ, van de Ven RA, Vermeulen JF, et al. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol. 2013 Oct;36(5):375–384.
   PubMed Web of Science ®Google Scholar
• Cordenonsi M, Zanconato F, Azzolin L, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011 Nov 11;147(4):759–772.
   PubMed Web of Science ®Google Scholar
• Kim SK, Jung WH, Koo JS. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Int J Clin Exp Pathol. 2014;7(6):3224–3234.
   PubMed Web of Science ®Google Scholar
• Wang X, Su L, Ou Q. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer. 2012 May;48(8):1227–1234.
   PubMed Web of Science ®Google Scholar
• Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–2761. DOI:10.1101/gad.1602907
   PubMed Web of Science ®Google Scholar
• Werneburg N, Gores GJ, Smoot RL. The Hippo Pathway and yap signaling: emerging concepts in regulation, signaling, and experimental targeting strategies with implications for hepatobiliary malignancies. Gene Expr. 2020 Jun 12;20(1):67–74.
   PubMed Web of Science ®Google Scholar
• He C, Lv X, Hua G, et al. YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression. Oncogene. 2015 Dec 10;34(50):6040–6054.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Moroishi T, de Jong PR, et al. YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1643–1648.
   PubMed Web of Science ®Google Scholar
• Kim HB, Kim M, Park YS, et al. Prostaglandin E(2) activates yap and a positive-signaling loop to promote colon regeneration after colitis but also carcinogenesis in mice. Gastroenterology. 2017 Feb;152(3):616–630.
   PubMed Web of Science ®Google Scholar
• Tamm C, Böwer N, Annerén C. Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. J Cell Sci. 2011 Apr 1;124(Pt 7):1136–1144.
   PubMed Web of Science ®Google Scholar
• Jorgensen MM, de la Puente P. Leukemia Inhibitory factor: an important cytokine in pathologies and cancer. Biomolecules. 2022;12(2):217.
   PubMed Web of Science ®Google Scholar
• Lei C, Lv S, Wang H, et al. Leukemia inhibitory factor receptor suppresses the metastasis of clear cell renal cell carcinoma through negative regulation of the yes-associated protein. DNA Cell Biol. 2018 Aug;37(8):659–669.
   PubMed Web of Science ®Google Scholar
• Wang D, Liu K, Yang Y, et al. Prognostic value of leukemia inhibitory factor and its receptor in pancreatic adenocarcinoma. Future Oncol. 2020 Jan;16(3):4461–4473.
   PubMed Web of Science ®Google Scholar
• H-X W, Cheng X, X-Q J, et al. LIFR promotes tumor angiogenesis by up-regulating IL-8 levels in colorectal cancer. Biochim Biophys Acta Mol Basis Dis. 2018;1864(9):2769–2784. DOI:10.1016/j.bbadis.2018.05.004
   PubMed Web of Science ®Google Scholar
• Liu SC, Hsu T, Chang YS, et al. Cytoplasmic LIF reprograms invasive mode to enhance NPC dissemination through modulating YAP1-FAK/PXN signaling. Nat Commun. 2018 Nov 30;9(1):5105.
   PubMedGoogle Scholar
• Bian SB, Yang Y, Liang WQ, et al. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR–Hippo–YAP pathway. Ann N Y Acad Sci. 2021;1484(1):74–89. DOI:10.1111/nyas.14466
   PubMed Web of Science ®Google Scholar
• Bressy C, Lac S, Nigri J, et al. LIF drives neural remodeling in pancreatic cancer and offers a new candidate biomarker. Cancer Res. 2018 Feb 15;78(4):909–921.
   PubMed Web of Science ®Google Scholar
• Chen JWC, Bhandari M, Astill DS, et al. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford). 2010;12(2):101–108. DOI:10.1111/j.1477-2574.2009.00140.x
   PubMed Web of Science ®Google Scholar
• Albrengues J, Bourget I, Pons C, et al. LIF mediates proinvasive activation of stromal fibroblasts in cancer. Cell Rep. 2014;7(5):1664–1678. DOI:10.1016/j.celrep.2014.04.036
   PubMed Web of Science ®Google Scholar
• Chu GC, Kimmelman AC, Hezel AF, et al. Stromal biology of pancreatic cancer. J Cell Biochem. 2007;101(4):887–907. DOI:10.1002/jcb.21209
   PubMed Web of Science ®Google Scholar
• Jaster R. Molecular regulation of pancreatic stellate cell function. Mol Cancer. 2004;3(1):1–8.
   PubMedGoogle Scholar
• Park JI, Strock CJ, Ball DW, et al. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol. 2003 Jan;23(2):543–554.
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010 Sep;16(9):1009–1017.
   PubMed Web of Science ®Google Scholar
• Totaro A, Castellan M, Battilana G, et al. YAP/TAZ link cell mechanics to Notch signalling to control epidermal stem cell fate. Nat Commun. 2017 May 17;8(1):15206.
   PubMedGoogle Scholar
• Nair HB, Kumar S. Targeting LIF/LIFR in pancreatic cancer. 2020. https://grantome.com/grant/NIH/R44-CA235991-01
   Google Scholar
• Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012 Mar 20;21(3):418–429.
   PubMed Web of Science ®Google Scholar
• Wu D, Guo J, Qi B, et al. TGF-β1 induced proliferation, migration, and ECM accumulation through the SNHG11/miR-34b/LIF pathway in human pancreatic stellate cells. Endocrine J. 2021;68(11):1347–1357. DOI:10.1507/endocrj.EJ21-0176
   PubMed Web of Science ®Google Scholar
• Liu R, Chen X, Du Y, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012;58(3):610–618. DOI:10.1373/clinchem.2011.172767
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang J, Li H, et al. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med. 2015;8(7):11683–11691.
   PubMed Web of Science ®Google Scholar
• Shi Y, Hunter S, Hunter T. Stem cell factor LIFted as a promising clinical target for cancer therapy. Mol Cancer Ther. 2019 Aug;18(8):1337–1340.
   PubMed Web of Science ®Google Scholar
• Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017 Mar 6;214(3):579–596.
   PubMed Web of Science ®Google Scholar
• Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014 Nov;13(11):828–851.
   PubMed Web of Science ®Google Scholar
• Toettcher JE, Weiner OD, Lim WA. Using optogenetics to interrogate the dynamic control of signal transmission by the Ras/Erk module. Cell. 2013 Dec 5;155(6):1422–1434.
   PubMed Web of Science ®Google Scholar
• Hunter SA, McIntosh BJ, Shi Y, et al. An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy. Commun Biol. 2021 Apr 12;4(1):452.
   PubMed Web of Science ®Google Scholar
• Borazanci E, Schram AM, Garralda E, et al. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. ESMO Open. 2022 Jul 31;7(4):100530. DOI:10.1016/j.esmoop.2022.100530
   PubMed Web of Science ®Google Scholar
• Candido J, Kar G, Zhang B, et al. AZD0171 (anti-LIF) combines productively with chemotherapy and anti-PD-L1 in mouse models of cancer. Cancer Res. 2022;82(12_Supplement):1293–1293. DOI:10.1158/1538-7445.AM2022-1293
   Web of Science ®Google Scholar
• Sinclair A, Hallett R, Giblin P, et al. Abstract 1751: mSC-1 is a first-in-class humanized monoclonal antibody that modulates the tumor microenvironment by inhibiting a novel cancer immunotherapy target. LIF Cancer Research. 2018;78(13_Supplement):1751–1751. DOI:10.1158/1538-7445.AM2018-1751
   PubMed Web of Science ®Google Scholar
• Loriot Y, Marabelle A, Guégan J, et al. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol. 2021;32(11):1381–1390. DOI:10.1016/j.annonc.2021.08.1748
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Wang L, Multani AS, et al. Trp53r172h and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005 May;7(5):469–483.
   PubMed Web of Science ®Google Scholar
• Lin J, Niimi Y, Clausi MG, et al. Neuroregenerative and protective functions of leukemia inhibitory factor in perinatal hypoxic-ischemic brain injury. Exp Neurol. 2020;330:113324.
   PubMed Web of Science ®Google Scholar
• Metcalfe SM, Strom TB, Williams A, et al. Multiple sclerosis and the LIF/IL-6 axis: use of nanotechnology to harness the tolerogenic and reparative properties of LIF. Nanobiomedicine (Rij). 2015;2(Godište 2015):2–5. DOI:10.5772/60622
   PubMedGoogle Scholar
• Bertola DR, Honjo RS, Baratela WA. Stüve-Wiedemann syndrome: update on clinical and genetic aspects. Mol Syndromol. 2016;7(1):12–18.
   PubMedGoogle Scholar
• O’Kane G, Macarulla T, Balogun F, et al. Abstract CT126: a phase 2 trial of first-line AZD0171 + durvalumab and chemotherapy (CT) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and CD8+ T cell infiltration. Cancer Res. 2022;82(12_Supplement):CT126–CT126. DOI:10.1158/1538-7445.AM2022-CT126
   Google Scholar
• Rolfe BE, Stamatiou S, World CJ, et al. Leukaemia inhibitory factor retards the progression of atherosclerosis. Cardiovasc Res. 2003;58(1):222–230. DOI:10.1016/S0008-6363(02)00832-5
   PubMed Web of Science ®Google Scholar
• Hallett R, Bonfill-Teixidor E, Iurlaro R, et al. Therapeutic targeting of LIF overcomes macrophage mediated immunosuppression of the local tumor microenvironment. Clin Cancer Res. 2023 Feb 16;29(4):791–804. DOI:10.1158/1078-0432.CCR-21-1888
   PubMed Web of Science ®Google Scholar
• Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019 Jun 11;10(1):2416.
   PubMedGoogle Scholar
• Hall BR, Cannon A, Thompson C, et al. Utilizing cell line-derived organoids to evaluate the efficacy of a novel LIFR-inhibitor, EC359 in targeting pancreatic tumor stroma. Genes Cancer. 2019;10(1–2):1–10. DOI:10.18632/genesandcancer.184
   PubMedGoogle Scholar
• Viswanadhapalli S, Luo Y, Sareddy GR, et al. EC359: a first-in-class small-molecule inhibitor for targeting oncogenic lifr signaling in triple-negative breast cancer novel small-molecule inhibitor of LIFR. Mol Cancer Ther. 2019;18(8):1341–1354. DOI:10.1158/1535-7163.MCT-18-1258
   PubMed Web of Science ®Google Scholar
• Yue X, Wu F, Wang J, et al. EC330, a small-molecule compound, is a potential novel inhibitor of LIF signaling. J Mol Cell Biol. 2020 Jul 3;12(6):477–480.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Li M, Viswanadhapalli S, Santhamma B, et al. LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. Commun Biol. 2021;4(1):1–14. DOI:10.1038/s42003-021-02741-7
   PubMed Web of Science ®Google Scholar
• Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018 Apr;15(4):234–248.
   PubMed Web of Science ®Google Scholar
• Biomedical B. Boston Biomedical, Inc. announces update on phase 3 CanStem111p study of napabucasin in patients with metastatic pancreatic cancer following interim analysis. 2019. https://scholar.google.com/scholar_lookup?journal=Boston+Biomedical%2C+Inc&title=Announces+Updates+on+Phase+3+Canstem111P+Study+of+Napabucasin+in+Patients+with+Metastatic+Pancreatic+Cancer+Following+Interim+Analysis&publication_year=2019&inst=12058184521150304743
   Google Scholar
• Hurwitz H, Van Cutsem E, Bendell J, et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: jANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018 Aug;36(4):683–695.
   PubMed Web of Science ®Google Scholar
• Ohtsuka S, Nakai-Futatsugi Y, Niwa H. LIF signal in mouse embryonic stem cells. JAKSTAT. 2015;4(2):1–9.
   PubMedGoogle Scholar
• Cherepkova MY, Sineva GS, Pospelov VA. Leukemia inhibitory factor (LIF) withdrawal activates mTOR signaling pathway in mouse embryonic stem cells through the MEK/ERK/TSC2 pathway. Cell Death Amp Dis. 2016;7(1):e2050–e2050. DOI:10.1038/cddis.2015.387
   PubMedGoogle Scholar
• Karime C, Wang J, Woodhead G, et al. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opin Investig Drugs. 2022 Jan 02;31(1):1–13.
   PubMed Web of Science ®Google Scholar
• Devaud C, John LB, Westwood JA, et al. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2013 Aug 1;2(8):e25961.
   PubMed Web of Science ®Google Scholar
• Gao W, Thompson L, Zhou Q, et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009;8(9):1444–1450. DOI:10.4161/cc.8.9.8348
   PubMed Web of Science ®Google Scholar
• Metcalfe Su M. LIF and the lung’s stem cell niche: is failure to use LIF to protect against COVID-19 agrave omission in managing the pandemic? Future Virology 15.10; 2020. p. 659–662.
   Google Scholar
• Metcalfe SM. Neuroprotective immunity: leukaemia inhibitory factor (LIF) as guardian of brain health. Medicine in Drug Discovery. 2019;2:100006.
   Google Scholar
• Zhang YS, Xin DE, Wang Z, et al. STAT 4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation. Embo J. 2019;38(6):1–20. DOI:10.15252/embj.201899595
   Web of Science ®Google Scholar